Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

NCT05509699 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-Stage Small Cell Lung Cancer

Interventions

DRUG: Surufatinib
DRUG: Anti-PD-1/L1

Sponsor

Hutchison Medipharma Limited